Matthew Swan, MD
Internal Medicine · Overland Park, KSNPI 1710144761
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,937, 5.6 times the $348 reported in 2020. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$1K
- Novo Nordisk$822
- Abbott$528
- Boehringer Ingelheim$474
- Pfizer$421
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,226100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 98 | $1,176 |
| Lilly USA, LLC | 56 | $1,001 |
| Novo Nordisk | 53 | $822 |
| Abbott | 11 | $528 |
| Boehringer Ingelheim | 24 | $474 |
| Pfizer | 36 | $421 |
| AstraZeneca | 18 | $374 |
| Amgen(2 entities) | 25 | $371 |
| GSK | 17 | $253 |
| Otsuka America Pharmaceutical, Inc. | 10 | $188 |
| Sanofi | 8 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $167 |
| Axsome Therapeutics, Inc. | 7 | $137 |
| Johnson & Johnson | 7 | $135 |
| Teva Pharmaceuticals USA, Inc. | 6 | $121 |
| Shield Therapeutics Inc | 2 | $110 |
| Boston Scientific | 5 | $95 |
| Amneal Pharmaceuticals LLC | 3 | $78 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $68 |
| Amarin Pharma, Inc. | 4 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Merck | 4 | $52 |
| Eisai Inc. | 3 | $51 |
| Exact Sciences | 3 | $49 |
| Dexcom, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Gilead | 1 | $20 |
| Viatris Specialty LLC | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Exeltis, USA Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$362
How this compares
$7,226 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $53,180 |
| JardianceEmpagliflozin | 51 | $49,067 |
| MounjaroTirzepatide | 41 | $42,077 |
| OzempicSemaglutide | 33 | $29,064 |
| LinzessLinaclotide | 25 | $27,717 |
| FarxigaDapagliflozin Propanediol | 15 | $23,743 |
| RybelsusSemaglutide | 12 | $22,758 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $19,795 |
| XareltoRivaroxaban | 12 | $11,122 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $5,452 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,881 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $4,671 |
| Celecoxib | 74 | $2,193 |
| Novolog FlexpenInsulin Aspart | 11 | $2,015 |
| Atorvastatin Calcium | 232 | $1,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $421 | $53,18042 claims |
| Novo NordiskOzempic, Rybelsus | $822 | $51,82245 claims |
| Boehringer IngelheimJardiance | $474 | $49,06751 claims |
| Lilly USA, LLCMounjaro | $1,001 | $42,07741 claims |
| AbbVieLinzess, Synthroid | $1,176 | $28,97146 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $253 | $24,67639 claims |
| AstraZenecaFarxiga | $374 | $23,74315 claims |
| Johnson & JohnsonXarelto | $135 | $11,12212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $78 | $1,405182 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Overland Park
- Herbert WaxmanOverland Park$82K
- Shadrach SmithOverland Park$27K
- David EdalatiOverland Park$21K
- Jennifer BrownOverland Park$9K
- Ammar KhalifaOverland Park$8K
- Bruce SalvaggioOverland Park$8K
- Vijaya SamuelOverland Park$8K
- Shazia Walijan MunirOverland Park$7K
- Victoria WeaverOverland Park$7K
- Michelle LesterOverland Park$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.